FS.07: Heart Failure Care for Novel Phenotypes (AHA 2026) - Oct 8, 2026 - Pres time: Nov 8, 2026; 09:30 AM - 10:45 AM; Location: Learning Studio 5‚ Science and Technology Hall‚ South Hall; In-Person; "IRONMET-HFpEF – Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Trial Primary Results SUMMIT – Tirzepatide and Reverse Remodeling of the Left Atrium and Right Heart in Obesity-Related Heart Failure With Preserved Ejection Fraction DAPARHT – Dapagliflozin for Renal Protection in Heart Transplant Recipients CADENCE – Effects of Sotatercept on Cardiac Structure and Function: Analysis of the CADENCE Study ELPIS II – A Phase 2b Randomized Clinical Trial to Evaluate the Efficacy and Safety of Laromestrocel as Adjunct Therapy During Stage II Palliation for Hypoplastic Left Heart Syndrome Semaglutide Ameliorates the Seminal Hemodynamic Features of Obesity-Related HFpEF: A Placebo Controlled Randomized Clinical Trial"
Late-breaking abstract • Cardiovascular • Genetic Disorders • Heart Failure • Obesity
|
|
Vanessa Blumer; MASSIMILIANO CAMILLI
|